Epidemiological study to evaluate the prevalence of BRAF V600 mutation in patients (pts) diagnosed with advanced melanoma (AM) in routine clinical practice in Spain.

被引：0
|
作者：
Arance Fernandez, Ana Maria
Alos Hernandez, Lucia
Cerezuela Fuentes, Pablo
Ortiz Reina, Sebastian
Ortega Izquierdo, Eugenia
Marti Laborda, Rosa Ma
Soberino, Jesus
Ferrer Fabrega, Berta
Rubio, Jordi
Perez Bueno, Fernando
Teresa Perez-Hoyos, Maria
Cancho Galan, Goikoane
Ballesteros Garcia, Ana Isabel
Fraga Fernandez, Javier
Marquez Rodas, Ivan
Parra, Veronica
Montagut Viladot, Clara
Bellosillo, Beatriz
Luis Rodriguez-Peralto, Jose
Lopez-Martin, Jose A.
机构：
[1] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[2] Hosp Clin Barcelona, Barcelona, Spain
[3] Hosp Santa Maria del Rosell, Cartagena, Spain
[4] Hosp Arnau Vilanova, Lleida, Spain
[5] Univ Hosp Vall dHebron, Barcelona, Spain
[6] Hosp Vall de Hebron, Barcelona, Spain
[7] Hosp Josep Trueta, Girona, Spain
[8] Hosp Dr Josep Trueta, Girona, Spain
[9] Basurto Univ Hosp, Bilbao, Spain
[10] Hosp Univ Basurto, Bilbao, Spain
[11] Hosp Univ La Princesa, Madrid, Spain
[12] Hosp La Princesa, Madrid, Spain
[13] Hosp Gregorio Maranon, Madrid, Spain
[14] Hosp del Mar, Barcelona, Spain
[15] Hosp del Mar, Dept Pathol, Barcelona, Spain
[16] Hosp Doce Octubre, Pathol Anat Serv, Madrid, Spain
[17] Hosp 12 Octubre, E-28041 Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20115
引用
收藏
页数：1
相关论文
共 40 条
  • [1] Treatment of patients with advanced melanoma harboring the BRAF V600 mutation
    Polowinczak-Przybylek, Joanna
    Potemski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 48 - 52
  • [2] BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
    Denise Zepeda-Lopez, Priscilla
    Cesar Salas-Alanis, Julio
    Toussaint-Caire, Sonia
    Gutierrez-Mendoza, Daniela
    Vega-Memije, Elisa
    Lino Silva, Saul
    Raul Fajardo-Ramirez, Oscar
    Alcazar, Gregorio
    Guadalupe Moreno-Trevino, Mara
    Barrera Saldana, Hugo Alberto
    CASE REPORTS IN ONCOLOGY, 2016, 9 (01): : 241 - 245
  • [3] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?
    Moreno-Ramirez, D.
    Fernandez-Orland, A.
    Ferrandiz, L.
    ACTAS DERMO-SIFILIOGRAFICAS, 2024, 115 (01): : T48 - T55
  • [4] The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
    Sobczuk, Pawel
    Kozak, Katarzyna
    Kopec, Sylwia
    Rogala, Pawel
    Switaj, Tomasz
    Kosela-Paterczyk, Hanna
    Gos, Aleksandra
    Tysarowski, Andrzej
    Rutkowski, Piotr
    CANCERS, 2022, 14 (03)
  • [5] Observational cross-sectional study evaluating the sociodemographic and clinical characteristics of patients with metastatic melanoma harboring a BRAF V600 mutation, treated with cobimetinib and vemurafenib based on routine clinical practice.
    Alamo de la Gala, Maria Carmen
    Ochenduszko, Sebastian
    Crespo, Guillermo
    Corral, Monica
    Oramas Rodriguez, Juana Maria
    Pilar Sancho, Maria
    Medina, Javier
    Garicano Goldaraz, Fernando
    Lopez Leiva, Pedro
    Campos Balea, Begona
    Adela Rodriguez, Analia
    Munoz-Couselo, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] The efficacy and safety of the combination of anti-BRAF agent and MEK inhibitor in advanced melanoma patients with BRAF V600 mutation: A meta-analysis.
    Xie, Changqing
    Mishriky, Basem Mourad Labib
    Chae, Phillip
    Atluri, Prashanti
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
    Larkin, James
    Lao, Christopher D.
    Urba, Walter J.
    McDermott, David F.
    Horak, Christine
    Jiang, Joel
    Wolchok, Jedd D.
    JAMA ONCOLOGY, 2015, 1 (04) : 433 - 440
  • [8] A single arm, open label, phase II, multicenter study to assess the detection of the BRAF V600 mutation on cfDNA from plasma in patients with advanced melanoma
    Rutkowski, P.
    Pauwels, P.
    Kerger, J.
    Jacobs, B.
    Maertens, G. G.
    Gadeyne, V.
    Liebert, S.
    Neyns, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 544 - 544
  • [9] COST-EFFECTIVENESS OF VEMURAFENIB AS A FIRST-LINE TREATMENT IN PATIENTS WITH BRAF V600 MUTATION-POSITIVE UNRESECTABLE OR METASTATIC MELANOMA IN SPAIN
    Rubio-Terres, C.
    Orofino, J.
    Armas, J.
    Parra, J.
    Rubio-Rodriguez, D.
    Grau, S.
    VALUE IN HEALTH, 2015, 18 (07) : A453 - A453
  • [10] Low BRAF V600 mutation prevalence in primary skin nodular melanoma in Indonesia: A real-Time PCR detection among Javanese patients
    Rinonce H.T.
    Aji R.P.M.
    Hayati N.
    Pudjohartono M.F.
    Kameswari B.
    Irianiwati
    BMC Proceedings, 13 (Suppl 11)
1234